James Condulis
Stock Analyst at Stifel
(2.23)
# 1,726
Out of 5,113 analysts
9
Total ratings
50%
Success rate
11.16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by James Condulis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NAMS NewAmsterdam Pharma Company | Maintains: Buy | $44 → $50 | $35.11 | +42.41% | 2 | Dec 16, 2025 | |
| XFOR X4 Pharmaceuticals | Maintains: Buy | $7.5 → $10 | $3.60 | +177.78% | 1 | Dec 5, 2025 | |
| AARD Aardvark Therapeutics | Initiates: Buy | $24 | $13.77 | +74.29% | 1 | Sep 29, 2025 | |
| CYTK Cytokinetics | Maintains: Buy | $87 → $96 | $62.72 | +53.06% | 2 | Sep 2, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Buy | $74 → $108 | $47.85 | +125.71% | 2 | Mar 28, 2025 | |
| EWTX Edgewise Therapeutics | Initiates: Hold | $30 | $25.55 | +17.42% | 1 | Jan 22, 2025 |
NewAmsterdam Pharma Company
Dec 16, 2025
Maintains: Buy
Price Target: $44 → $50
Current: $35.11
Upside: +42.41%
X4 Pharmaceuticals
Dec 5, 2025
Maintains: Buy
Price Target: $7.5 → $10
Current: $3.60
Upside: +177.78%
Aardvark Therapeutics
Sep 29, 2025
Initiates: Buy
Price Target: $24
Current: $13.77
Upside: +74.29%
Cytokinetics
Sep 2, 2025
Maintains: Buy
Price Target: $87 → $96
Current: $62.72
Upside: +53.06%
Soleno Therapeutics
Mar 28, 2025
Maintains: Buy
Price Target: $74 → $108
Current: $47.85
Upside: +125.71%
Edgewise Therapeutics
Jan 22, 2025
Initiates: Hold
Price Target: $30
Current: $25.55
Upside: +17.42%